The Myocardin activators represent a diverse group of compounds that modulate the activity of Myocardin, a key transcriptional coactivator in the regulation of smooth muscle differentiation. One notable member of this class is CCG-1423, a Rho/MRTF/SRF pathway inhibitor. By blocking the RhoA signaling pathway, CCG-1423 indirectly activates Myocardin, enabling its interaction with SRF and enhancing the transcription of genes crucial for smooth muscle development. Several compounds in this class, such as Y-27632 and CK-666, target actin dynamics. Y-27632, a ROCK inhibitor, prevents the phosphorylation and inactivation of Myocardin by inhibiting ROCK, while CK-666 disrupts actin polymerization, releasing Myocardin for transcriptional activity. These compounds showcase the importance of actin modulation in regulating Myocardin function and subsequently influencing smooth muscle differentiation.
C646, a selective inhibitor of p300/CBP HAT, contributes to Myocardin activation by altering its acetylation status. Inhibition of p300/CBP enhances Myocardin stability and activity, leading to increased transcription of genes associated with smooth muscle differentiation. Furthermore, compounds like CGP 57380 and Jasplakinolide target the MAPK pathway and actin cytoskeleton, respectively, indirectly activating Myocardin and promoting its role in smooth muscle development. SIS3 and SB-431542, inhibitors of Smad3 phosphorylation and TGF-β receptor, respectively, showcase the interplay between TGF-β signaling and Myocardin activation. Inhibition of these pathways prevents the inactivation of Myocardin, allowing it to translocate to the nucleus and enhance the expression of genes involved in smooth muscle differentiation. In summary, the Myocardin activators represent a nuanced collection of compounds targeting various pathways, including RhoA, actin dynamics, HAT activity, MAPK, and TGF-β signaling. The modulation of these pathways contributes to the intricate control of Myocardin's transcriptional coactivator function, shedding light on potential strategies for influencing smooth muscle differentiation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646 is a selective inhibitor of p300/CBP HAT. By blocking p300/CBP, it indirectly activates Myocardin. Inhibition of p300/CBP alters the acetylation status of Myocardin, enhancing its stability and activity. This modification leads to increased transcription of genes involved in smooth muscle differentiation. | ||||||
CGP 57380 | 522629-08-9 | sc-202993 | 5 mg | $172.00 | 6 | |
CGP 57380 inhibits RSK, a downstream effector of the MAPK pathway. By suppressing RSK, it indirectly activates Myocardin. Inhibition of RSK prevents the phosphorylation and inactivation of Myocardin, allowing it to translocate to the nucleus and enhance the transcription of genes involved in smooth muscle differentiation. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes F-actin filaments. Its inhibition disrupts the actin cytoskeleton, indirectly activating Myocardin. Jasplakinolide prevents the sequestration of Myocardin by actin filaments, allowing Myocardin to translocate to the nucleus and facilitate the transcription of genes associated with smooth muscle differentiation. | ||||||
Smad3 Inhibitor, SIS3 | 1009104-85-1 | sc-222318 | 1 mg | $257.00 | 36 | |
SIS3 inhibits Smad3 phosphorylation, indirectly activating Myocardin through TGF-β signaling. Inhibition of Smad3 prevents its interaction with Myocardin, releasing Myocardin to form a transcriptional complex with SRF. This enhances the expression of target genes involved in smooth muscle differentiation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 is a TGF-β receptor inhibitor. By blocking TGF-β signaling, it indirectly activates Myocardin. Inhibition of TGF-β prevents the downstream phosphorylation and inactivation of Myocardin, allowing it to translocate to the nucleus and enhance the transcription of genes associated with smooth muscle differentiation. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is a myosin light chain kinase (MLCK) inhibitor. By inhibiting MLCK, it indirectly activates Myocardin through modulation of actin dynamics. MLCK inhibition prevents actin polymerization, freeing Myocardin to translocate to the nucleus and enhance the transcription of genes involved in smooth muscle differentiation. | ||||||